Avestar Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Avestar Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,635	Closed	-$682K	–	497
2023 Q4	$682K	Sell	7,635 -70	-0.9%	-$5.2K	0.08%	162
2023 Q3	$563K	Buy	7,705 +100	+1%	+$7.99K	0.08%	156
2023 Q2	$633K	Sell	7,605 -500	-6%	-$41.8K	0.1%	126
2023 Q1	$618K	Sell	8,105 -265	-3%	-$22K	0.11%	122
2022 Q4	$695K	Sell	8,370 -50	-0.6%	-$4.05K	0.13%	110
2022 Q3	$668K	Buy	8,420 +200	+2%	+$16.9K	0.17%	88
2022 Q2	$610K	Buy	+8,220	New	+$617K	0.15%	103
2018 Q4	–	Sell	-19,505	Closed	-$1.85M	–	1018
2018 Q3	$1.85M	Buy	19,505 +4,255	+28%	+$413K	1.07%	24
2018 Q2	$1.43M	Buy	15,250 +5,810	+62%	+$534K	0.91%	27
2018 Q1	$813K	Buy	9,440 +2,571	+37%	+$235K	0.53%	36
2017 Q4	$578K	Buy	+6,869	New	+$575K	0.43%	35

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Avestar Capital's XBI Position: Q1 2024 in Review

Avestar Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 7,635 shares — an estimated $682K sold.

Avestar Capital first reported a position in XBI in Q4 2017 and held it in 11 quarters. The position peaked at $1.85M in Q3 2018. 781 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

Avestar Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
Avestar Capital sold 7,635 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $682K.
Avestar Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and held it in 11 quarters.
Avestar Capital's State Street SPDR S&P Biotech ETF position peaked at $1.85M in Q3 2018.
781 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on Avestar Capital's 13F filing for Q1 2024, filed 10 May 2024.